The company, which is based in Hoofddorp in the Netherlands, was founded in 2016 and is part of the Frederik Paulsen business interests which consists of a number of healthcare companies including Ferring Pharmaceuticals.

Amzell has a particular interest in developing well-characterized active substances utilizing innovative platform drug delivery technologies, which provide more effective drug delivery, increased efficacy, and improved safety and compliance.